130 related articles for article (PubMed ID: 10601506)
1. Combination therapy with efavirenz, nelfinavir, and nucleoside reverse-transcriptase inhibitors in children infected with human immunodeficiency virus type 1. Pediatric AIDS Clinical Trials Group 382 Team.
Starr SE; Fletcher CV; Spector SA; Yong FH; Fenton T; Brundage RC; Manion D; Ruiz N; Gersten M; Becker M; McNamara J; Mofenson LM; Purdue L; Siminski S; Graham B; Kornhauser DM; Fiske W; Vincent C; Lischner HW; Dankner WM; Flynn PM
N Engl J Med; 1999 Dec; 341(25):1874-81. PubMed ID: 10601506
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of efavirenz and nelfinavir in HIV-infected children participating in an area-under-the-curve controlled trial.
Fletcher CV; Brundage RC; Fenton T; Alvero CG; Powell C; Mofenson LM; Spector SA
Clin Pharmacol Ther; 2008 Feb; 83(2):300-6. PubMed ID: 17609682
[TBL] [Abstract][Full Text] [Related]
3. Association of Virologic Failure and Nonnucleoside Reverse Transcriptase Inhibitor Resistance Found in Antiretroviral-Naive Children Infected With Human Immunodeficiency Virus and Given Efavirenz-Based Treatment.
Higa N; Pelz A; Birch D; Beck IA; Sils T; Samson P; Bwakura-Dangarembizi M; Bolton-Moore C; Capparelli E; Chadwick E; Frenkel LM
J Pediatric Infect Dis Soc; 2020 Apr; 9(2):261-264. PubMed ID: 31194860
[TBL] [Abstract][Full Text] [Related]
4. Mitochondrial genomics and CD4 T-cell count recovery after antiretroviral therapy initiation in AIDS clinical trials group study 384.
Grady BJ; Samuels DC; Robbins GK; Selph D; Canter JA; Pollard RB; Haas DW; Shafer R; Kalams SA; Murdock DG; Ritchie MD; Hulgan T;
J Acquir Immune Defic Syndr; 2011 Dec; 58(4):363-70. PubMed ID: 21792066
[TBL] [Abstract][Full Text] [Related]
5. Bayesian parameter estimates of nelfinavir and its active metabolite, hydroxy-tert-butylamide, in infants perinatally infected with human immunodeficiency virus type 1.
Payen S; Faye A; Compagnucci A; Giaquinto C; Gibbs D; Gomeni R; Bressolle F; Jacqz-Aigrain E
Antimicrob Agents Chemother; 2005 Feb; 49(2):525-35. PubMed ID: 15673728
[TBL] [Abstract][Full Text] [Related]
6. A population pharmacokinetic analysis of nelfinavir mesylate in human immunodeficiency virus-infected patients enrolled in a phase III clinical trial.
Jackson KA; Rosenbaum SE; Kerr BM; Pithavala YK; Yuen G; Dudley MN
Antimicrob Agents Chemother; 2000 Jul; 44(7):1832-7. PubMed ID: 10858338
[TBL] [Abstract][Full Text] [Related]
7. Antiretroviral drugs from multiple classes induce loss of excitatory synapses between hippocampal neurons in culture.
McMullan HM; Gansemer BM; Thayer SA
Front Pharmacol; 2024; 15():1369757. PubMed ID: 38533258
[No Abstract] [Full Text] [Related]
8. [Diarrhea and HIV infection].
Dellamonica P
Med Mal Infect; 2003 Feb; 33():105-110. PubMed ID: 38620209
[TBL] [Abstract][Full Text] [Related]
9. Frequent Development of Broadly Neutralizing Antibodies in Early Life in a Large Cohort of Children With Human Immunodeficiency Virus.
Lucier A; Fong Y; Li SH; Dennis M; Eudailey J; Nelson A; Saunders K; Cunningham CK; McFarland E; McKinney R; Moody MA; LaBranche C; Montefiori D; Permar SR; Fouda GG
J Infect Dis; 2022 May; 225(10):1731-1740. PubMed ID: 34962990
[TBL] [Abstract][Full Text] [Related]
10. The Pharmacogenetics of Efavirenz Metabolism in Children: The Potential Genetic and Medical Contributions to Child Development in the Context of Long-Term ARV Treatment.
Tan M; Bowers M; Thuma P; Grigorenko EL
New Dir Child Adolesc Dev; 2020 May; 2020(171):107-133. PubMed ID: 32657046
[TBL] [Abstract][Full Text] [Related]
11. CYP2B6 Genetic Polymorphisms, Depression, and Viral Suppression in Adults Living with HIV Initiating Efavirenz-Containing Antiretroviral Therapy Regimens in Uganda: Pooled Analysis of Two Prospective Studies.
Chang JL; Lee SA; Tsai AC; Musinguzi N; Muzoora C; Bwana B; Boum Y; Haberer JE; Hunt PW; Martin J; Bangsberg DR; Kroetz DL; Siedner MJ
AIDS Res Hum Retroviruses; 2018 Nov; 34(11):982-992. PubMed ID: 29973058
[TBL] [Abstract][Full Text] [Related]
12. Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.
Bienczak A; Denti P; Cook A; Wiesner L; Mulenga V; Kityo C; Kekitiinwa A; Gibb DM; Burger D; Walker AS; McIlleron H
J Acquir Immune Defic Syndr; 2016 Oct; 73(2):161-8. PubMed ID: 27116047
[TBL] [Abstract][Full Text] [Related]
13. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
[TBL] [Abstract][Full Text] [Related]
14. Antiretroviral treatment in HIV-1 infected pediatric patients: focus on efavirenz.
Larru B; Eby J; Lowenthal ED
Pediatric Health Med Ther; 2014 May; 5():29-42. PubMed ID: 25937791
[TBL] [Abstract][Full Text] [Related]
15. Safety and effectiveness of combination antiretroviral therapy during the first year of treatment in HIV-1 infected Rwandan children: a prospective study.
Mutwa PR; Boer KR; Asiimwe-Kateera B; Tuyishimire D; Muganga N; Lange JM; van de Wijgert J; Asiimwe A; Reiss P; Geelen SP
PLoS One; 2014; 9(11):e111948. PubMed ID: 25365302
[TBL] [Abstract][Full Text] [Related]
16. Effects of rifampin-based antituberculosis therapy on plasma efavirenz concentrations in children vary by CYP2B6 genotype.
McIlleron HM; Schomaker M; Ren Y; Sinxadi P; Nuttall JJ; Gous H; Moultrie H; Eley B; Merry C; Smith P; Haas DW; Maartens G
AIDS; 2013 Jul; 27(12):1933-40. PubMed ID: 24180002
[TBL] [Abstract][Full Text] [Related]
17. Pharmacometric characterization of efavirenz developmental pharmacokinetics and pharmacogenetics in HIV-infected children.
Salem AH; Fletcher CV; Brundage RC
Antimicrob Agents Chemother; 2014; 58(1):136-43. PubMed ID: 24145522
[TBL] [Abstract][Full Text] [Related]
18. Rate of candidiasis among HIV-infected children in Spain in the era of highly active antiretroviral therapy (1997-2008).
Álvaro-Meca A; Jensen J; Micheloud D; Díaz A; Gurbindo D; Resino S
BMC Infect Dis; 2013 Mar; 13():115. PubMed ID: 23510319
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
